PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

This study is testing whether combining immunotherapy (a PD-1 blocking drug) with chemotherapy and radiation can improve outcomes for people whose nasopharyngeal cancer (a cancer at the back of the nose and throat) has returned locally after prior treatment. **You may be eligible if...** - Your nasopharyngeal cancer has come back locally at least 1 year after completing prior treatment - You are not a candidate for surgery - Your recurrent cancer is at a locally advanced stage (rII through rIVa) - You are in good general health (ECOG 0-1), have not yet received treatment for the recurrence, and have adequate blood and organ function **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have already received treatment targeting the recurrence - You have contraindications to immunotherapy or radiation Talk to your doctor to see if this trial is right for you.